The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127).
 
James C. Yao
Consulting or Advisory Role - Ipsen; Lexicon; Novartis
Research Funding - Novartis
 
Katherine Guthrie
No Relationships to Disclose
 
Cesar Moran
No Relationships to Disclose
 
Jonathan R. Strosberg
Honoraria - Genentech
 
Matthew H. Kulke
Consulting or Advisory Role - Ipsen; Novartis
 
Jennifer A. Chan
Stock and Other Ownership Interests - Merck
Consulting or Advisory Role - Bayer (I); Pfizer (I); POZEN (I)
Research Funding - Novartis; Sanofi
 
Noelle K. LoConte
No Relationships to Disclose
 
Robert R. McWilliams
Research Funding - Aduro Biotech (Inst); Genentech (Inst); Lilly (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); PRISM BioLab (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Edward M. Wolin
Consulting or Advisory Role - Celgene; Ipsen; Novartis
 
Bassam Ibrahim Mattar
No Relationships to Disclose
 
Shannon McDonough
No Relationships to Disclose
 
Helen X. Chen
Consulting or Advisory Role - Ipsen
 
Charles David Blanke
Travel, Accommodations, Expenses - Novartis
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Sirtex Medical
Speakers' Bureau - Genomic Health